Market Research Logo

Sepsis - Pipeline Review, H2 2015

Sepsis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Sepsis - Pipeline Review, H2 2015’, provides an overview of the Sepsis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sepsis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Sepsis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Sepsis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Sepsis Overview
Therapeutics Development
Pipeline Products for Sepsis - Overview
Pipeline Products for Sepsis - Comparative Analysis
Sepsis - Therapeutics under Development by Companies
Sepsis - Therapeutics under Investigation by Universities/Institutes
Sepsis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Sepsis - Products under Development by Companies
Sepsis - Products under Investigation by Universities/Institutes
Sepsis - Companies Involved in Therapeutics Development
Adrenomed AG
Altor BioScience Corporation
Am-Pharma B.V.
Arch Biopartners, Inc.
Asahi Kasei Pharma Corp.
Biomedica Management Corporation
Cell2B S.A.
Chiesi Farmaceutici SpA
Chiome Bioscience, Inc.
Cilian AG
Cognosci, Inc.
Diomune S.L
Endacea, Inc.
Evec, Inc.
Huons Co., Ltd.
Immune Response BioPharma, Inc.
Immunethep, SA
ImmunNovative Developments SL
InflaRx GmbH
Integrated BioTherapeutics, Inc.
ISU ABXIS Co.,Ltd.
Lead Discovery Center GmbH
Navigen Pharmaceuticals, Inc.
Novadiscovery SAS
Ocata Therapeutics, Inc.
OncoImmune, Inc.
Opsona Therapeutics Limited
ProThera Biologics, LLC.
Ribomic Inc.
Silence Therapeutics Plc
Stemedica Cell Technologies, Inc.
Syntiron LLC
Takeda Pharmaceutical Company Limited
TiGenix NV
VBS Pharmaceuticals
XImmune AB
Sepsis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
3K3A-APC - Drug Profile
7-H9 - Drug Profile
AB-022 - Drug Profile
AcPepA - Drug Profile
adrecizumab - Drug Profile
Alpha B Crystalline - Drug Profile
ALT-836 - Drug Profile
AM/AMBP-1 - Drug Profile
Aspidasept - Drug Profile
Atu-111 - Drug Profile
bacterial sepsis vaccine - Drug Profile
BaxB-01 - Drug Profile
BaxG-03 - Drug Profile
BaxM-159 - Drug Profile
BRL-44408 - Drug Profile
BTZO-2 - Drug Profile
CAR Peptide - Drug Profile
ceftaroline fosamil - Drug Profile
CN-16 - Drug Profile
COG-133 - Drug Profile
Cx-611 - Drug Profile
Drug for Sepsis - Drug Profile
Drugs for Sepsis - Drug Profile
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
Drugs to Inhibit Sialidase for Sepsis - Drug Profile
Escherichia coli vaccine - Drug Profile
EV-007156 - Drug Profile
Glyco-23 - Drug Profile
HBN-1 - Drug Profile
HBN-3 - Drug Profile
HBN-4 - Drug Profile
HU-003 - Drug Profile
IFX-1 - Drug Profile
ImmStem - Drug Profile
ImmuneSafe - Drug Profile
IND-005 - Drug Profile
IND-006 - Drug Profile
IR-999 - Drug Profile
ISU-201 - Drug Profile
Klebsiella pneumoniae vaccine - Drug Profile
L-97-1 - Drug Profile
LB-1148 - Drug Profile
LR-17 - Drug Profile
M-33 - Drug Profile
meropenem - Drug Profile
Mesenchymal Stem Cells - Drug Profile
Metablok - Drug Profile
Micselon - Drug Profile
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Nanotherapeutics - Drug Profile
NAV-838 - Drug Profile
OPN-305 - Drug Profile
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
Polysaccharide for Sepsis - Drug Profile
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile
RBM-005 - Drug Profile
Recombinant Enzyme to Replace Alkaline Phosphatase for Sepsis - Drug Profile
Recombinant Human Alkaline Phosphatase - Drug Profile
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile
Recombinant Protein for Sepsis - Drug Profile
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile
Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile
SAN-101 - Drug Profile
Slit2N - Drug Profile
Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile
Small Molecule to Inhibit DDAH1 for Sepsis - Drug Profile
Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile
staphylococcus aureus (bivalent) vaccine - Drug Profile
Stem Cell Therapy for Autoimmune Diseases - Drug Profile
Synthetic Peptide to Inhibit TREM-1 for Cancer and Infectious Diseases - Drug Profile
Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile
Synthetic Peptides for Infectious Disease - Drug Profile
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile
Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile
Synthetic Peptides to Inhibit LPS for Bacterial and Viral Infections - Drug Profile
TF-0003 - Drug Profile
thrombomodulin alfa - Drug Profile
TRX-306 - Drug Profile
vancomycin hydrochloride - Drug Profile
Yersinia pestis vaccine - Drug Profile
Sepsis - Recent Pipeline Updates
Sepsis - Dormant Projects
Sepsis - Discontinued Products
Sepsis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Sepsis, H2 2015
Number of Products under Development for Sepsis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Sepsis - Pipeline by Adrenomed AG, H2 2015
Sepsis - Pipeline by Altor BioScience Corporation, H2 2015
Sepsis - Pipeline by Am-Pharma B.V., H2 2015
Sepsis - Pipeline by Arch Biopartners, Inc., H2 2015
Sepsis - Pipeline by Asahi Kasei Pharma Corp., H2 2015
Sepsis - Pipeline by Biomedica Management Corporation, H2 2015
Sepsis - Pipeline by Cell2B S.A. , H2 2015
Sepsis - Pipeline by Chiesi Farmaceutici SpA, H2 2015
Sepsis - Pipeline by Chiome Bioscience, Inc., H2 2015
Sepsis - Pipeline by Cilian AG, H2 2015
Sepsis - Pipeline by Cognosci, Inc., H2 2015
Sepsis - Pipeline by Diomune S.L, H2 2015
Sepsis - Pipeline by Endacea, Inc., H2 2015
Sepsis - Pipeline by Evec, Inc., H2 2015
Sepsis - Pipeline by Huons Co., Ltd., H2 2015
Sepsis - Pipeline by Immune Response BioPharma, Inc., H2 2015
Sepsis - Pipeline by Immunethep, SA, H2 2015
Sepsis - Pipeline by ImmunNovative Developments SL, H2 2015
Sepsis - Pipeline by InflaRx GmbH, H2 2015
Sepsis - Pipeline by Integrated BioTherapeutics, Inc., H2 2015
Sepsis - Pipeline by ISU ABXIS Co.,Ltd., H2 2015
Sepsis - Pipeline by Lead Discovery Center GmbH, H2 2015
Sepsis - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015
Sepsis - Pipeline by Novadiscovery SAS, H2 2015
Sepsis - Pipeline by Ocata Therapeutics, Inc., H2 2015
Sepsis - Pipeline by OncoImmune, Inc., H2 2015
Sepsis - Pipeline by Opsona Therapeutics Limited, H2 2015
Sepsis - Pipeline by ProThera Biologics, LLC., H2 2015
Sepsis - Pipeline by Ribomic Inc., H2 2015
Sepsis - Pipeline by Silence Therapeutics Plc, H2 2015
Sepsis - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Sepsis - Pipeline by Syntiron LLC, H2 2015
Sepsis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Sepsis - Pipeline by TiGenix NV, H2 2015
Sepsis - Pipeline by VBS Pharmaceuticals, H2 2015
Sepsis - Pipeline by XImmune AB, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Sepsis Therapeutics - Recent Pipeline Updates, H2 2015
Sepsis - Dormant Projects, H2 2015
Sepsis - Dormant Projects (Contd..1), H2 2015
Sepsis - Dormant Projects (Contd..2), H2 2015
Sepsis - Dormant Projects (Contd..3), H2 2015
Sepsis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Sepsis, H2 2015
Number of Products under Development for Sepsis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report